These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

576 related items for PubMed ID: 15811210

  • 1. How treatment priorities influence triptan preferences in clinical practice: perspectives of migraine sufferers, neurologists, and primary care physicians.
    Lipton RB, Cutrer FM, Goadsby PJ, Ferrari MD, Dodick DW, McCrory D, Liberman JN, Williams P.
    Curr Med Res Opin; 2005 Mar; 21(3):413-24. PubMed ID: 15811210
    [Abstract] [Full Text] [Related]

  • 2. Priorities for triptan treatment attributes and the implications for selecting an oral triptan for acute migraine: a study of US primary care physicians (the TRIPSTAR Project).
    Cutrer FM, Goadsby PJ, Ferrari MD, Lipton RB, Dodick DW, McCrory D, Williams P.
    Clin Ther; 2004 Sep; 26(9):1533-45. PubMed ID: 15531016
    [Abstract] [Full Text] [Related]

  • 3. TRIPSTAR: prioritizing oral triptan treatment attributes in migraine management.
    Goadsby PJ, Dodick DW, Ferrari MD, McCrory DC, Williams P.
    Acta Neurol Scand; 2004 Sep; 110(3):137-43. PubMed ID: 15285768
    [Abstract] [Full Text] [Related]

  • 4. Patterns of use of triptans and reasons for switching them in a tertiary care migraine population.
    Sheftell FD, Feleppa M, Tepper SJ, Volcy M, Rapoport AM, Bigal ME.
    Headache; 2004 Sep; 44(7):661-8. PubMed ID: 15209687
    [Abstract] [Full Text] [Related]

  • 5. Almotriptan: meeting today's needs in acute migraine treatment.
    Láinez MJ.
    Expert Rev Neurother; 2007 Dec; 7(12):1659-73. PubMed ID: 18052762
    [Abstract] [Full Text] [Related]

  • 6. Consistent efficacy, tolerability, and high levels of satisfaction with almotriptan 12.5 mg when used to treat multiple migraine attacks in routine clinical practice.
    Diener HC.
    Headache; 2005 Jun; 45(6):624-31. PubMed ID: 15953293
    [Abstract] [Full Text] [Related]

  • 7. Migraine treatment with rizatriptan and non-triptan usual care medications: a pharmacy-based study.
    Cady R, Martin V, Adelman J, Diamond M, Sajjan S, Hu XH.
    Headache; 2004 Oct; 44(9):900-7. PubMed ID: 15447699
    [Abstract] [Full Text] [Related]

  • 8. Focus on trial endpoints of clinical relevance and the use of almotriptan for the acute treatment of migraine.
    Sandrini G, Dahlöf CG, Mathew N, Nappi G.
    Int J Clin Pract; 2005 Nov; 59(11):1356-65. PubMed ID: 16236092
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Management costs of chest and CNS-related adverse events associated with the treatment of acute migraine attacks with oral triptans].
    Slof J, Badia X, Lainez-Andres JM, Galvan J, Heras J.
    Neurologia; 2005 Nov; 20(6):290-8. PubMed ID: 16007512
    [Abstract] [Full Text] [Related]

  • 11. Using patient-centered endpoints to determine the cost-effectiveness of triptans for acute migraine therapy.
    Kelman L, Von Seggern RL.
    Am J Ther; 2006 Nov; 13(5):411-7. PubMed ID: 16988536
    [Abstract] [Full Text] [Related]

  • 12. A pharmacoeconomic evaluation of oral triptans in the treatment of migraine in Italy.
    Gori S, Morelli N, Acuto G, Caiola F, Iudice A, Murri L.
    Minerva Med; 2006 Dec; 97(6):467-77. PubMed ID: 17213783
    [Abstract] [Full Text] [Related]

  • 13. Time to pain freedom and onset of pain relief with rizatriptan 10 mg and prescription usual-care oral medications in the acute treatment of migraine headaches: a multicenter, prospective, open-label, two-attack, crossover study.
    Bell CF, Foley KA, Barlas S, Solomon G, Hu XH.
    Clin Ther; 2006 Jun; 28(6):872-80. PubMed ID: 16860170
    [Abstract] [Full Text] [Related]

  • 14. Almotriptan: a review of pharmacology, clinical efficacy, and tolerability.
    Von S.
    Am J Manag Care; 2002 Feb; 8(3 Suppl):S74-9. PubMed ID: 11859907
    [Abstract] [Full Text] [Related]

  • 15. Clinical benefits of early triptan therapy for migraine.
    Láinez M.
    Cephalalgia; 2004 Feb; 24 Suppl 2():24-30. PubMed ID: 15595991
    [Abstract] [Full Text] [Related]

  • 16. Economic analysis of triptan therapy for acute migraine: a Medicaid perspective.
    Mullins CD, Subedi PR, Healey PJ, Sanchez RJ.
    Pharmacotherapy; 2007 Aug; 27(8):1092-101. PubMed ID: 17655509
    [Abstract] [Full Text] [Related]

  • 17. Predictors of adherence to triptans: factors of sustained vs lapsed users.
    Cady RK, Maizels M, Reeves DL, Levinson DM, Evans JK.
    Headache; 2009 Mar; 49(3):386-94. PubMed ID: 19220501
    [Abstract] [Full Text] [Related]

  • 18. Do family physicians fail to provide triptans for patients with migraine?
    Walling A, Woolley DC, Molgaard C, Kallail KJ.
    J Fam Pract; 2006 Dec; 55(12):1057-62. PubMed ID: 17137542
    [Abstract] [Full Text] [Related]

  • 19. Economic comparison of oral triptans for management of acute migraine: implications for managed care.
    Reeder CE, Steadman S, Goldfarb SD.
    Am J Manag Care; 2002 Feb; 8(3 Suppl):S80-4. PubMed ID: 11859908
    [Abstract] [Full Text] [Related]

  • 20. Times to pain relief and pain freedom with rizatriptan 10 mg and other oral triptans.
    Ng-Mak DS, Hu XH, Chen Y, Ma L, Solomon G.
    Int J Clin Pract; 2007 Jul; 61(7):1091-111. PubMed ID: 17537184
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.